Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and willing to participate.
- You have been diagnosed with invasive breast cancer that has spread to other parts of the body.
- Your cancer is HER2-negative (a specific protein test result).
- You have at least two measurable tumors, and at least one tumor can safely receive radiation therapy (not in a bone).
- You have had at least two previous treatments for your cancer, and it continues to grow.
- You have good overall health (able to care for yourself and expected to live more than 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
This study tests combining a special heat treatment (thermal therapy) with immunotherapy to see if it works better for HER2-negative breast cancer that has spread to the liver. It may help people who have already tried other treatments and whose cancer has gotten worse.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This trial tests giving chemotherapy, an immunotherapy drug (PD-1 inhibitor), and different types of radiation before surgery for people with a common type of breast cancer (HR+/HER2-). The goal is to see which radiation plan works best to shrink tumors.
This trial tests a combination of chemotherapy (docetaxel and carboplatin) plus two targeted drugs (Inetetamab and Pyrotinib) for people with locally advanced HER2-positive breast cancer that has not spread to other parts of the body. The goal is to see if this powerful combo can shrink the tumor before surgery or other treatments.
This trial tests combining two treatments—an immunotherapy drug (Toripalimab) and radiation—before surgery for a certain type of breast cancer (HR+, HER2-negative) that has spread to lymph nodes. The goal is to see if this combination helps shrink the tumor more than standard therapy alone.
Hear when a new Breast Cancer, Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.